Business Context and Reporting Period
Indaptus Therapeutics, Inc. (INDP), a Delaware corporation, filed this Form 8-K on May 15, 2026. The filing serves to announce the Company's financial results for the quarter ended March 31, 2026, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached Press Release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that business updates and financial results for the quarter ended March 31, 2026, were issued.
Guidance, Outlook, and Risks
The filing notes that the accompanying Press Release contains forward-looking statements regarding the Company's expectations, plans, and prospects. The text explicitly states that the information in this Current Report (including the Press Release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 financial figures (revenue, net loss, cash position).
- Verify the Company's cash runway and burn rate based on the detailed results in the Press Release.
- Assess the specific forward-looking statements and clinical or business updates mentioned in the Press Release.
- Confirm any changes in capital structure or financing activities not detailed in this summary.